Virologic and immunologic response to antiretroviral therapy and predictors of HIV type 1 drug resistance in children receiving treatment in Abidjan, Côte d'Ivoire

AIDS Research and Human Retroviruses

Volumn 24, Issue 7, 2008, Pages 911-917

  Adjé Touré, Christiane ^a   Hanson, Debra L ^b   Talla Nzussouo, N ^a   Borget, Marie Yolande ^a   Kouadio, Léonard Ya ^a   Tossou, Odette ^a   Fassinou, Patricia ^c   Bissagnene, Emmanuel ^d   Kadio, Auguste ^d   Nolan, Monica L ^a,e   Nkengasong, John N ^a,b,e  

^a Project RETRO CI   (Côte d’Ivoire)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c University Teaching Hospital of Yopougon   (Côte d’Ivoire)

^d Infectious Disease Unit   (Côte d’Ivoire)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADOLESCENT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; CHILD CARE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; COTE D'IVOIRE; FEMALE; FOLLOW UP; GENOTYPE; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; INFANT; MAJOR CLINICAL STUDY; MALE; MUTATION; NEWBORN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; TREATMENT DURATION; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ADOLESCENT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; COTE D'IVOIRE; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 48749107884     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0264     Document Type: Article

References (20)

1. UNAIDS AIDS epidemic update, December 2005 http://www.unaids.org/Epi2005/ doc/report_pdf.html.
2. UNICEF Unite for children, unite against AIDS campaign, 2005 http://www.unicef.org/uniteforchildren/makeadifference/makediff_29274.html.
3. Fassinou P, Elenga N, Rouet F, et al.: Highly active anti-retroviral therapies among HIV-1-infected children in Abidjan, Cote d'Ivoire. AIDS 2004;18:1905-1913.
4. Chaix ML, Rouet F, Kouakousui KA, et al.: Genotypic human immunodeficiency virus type I drug resistance in highly active antiretroviral therapy treated children in Abidjan Cote d'Ivoire. Pediatr Inf Dis J 2005;24:1072-1076.
5. Resino S, Bellon JM, Gurbindo D, et al.: Viral load and CD4+ T lymphocyte response to highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children: An observational study. Clin Infect Dis 2003;37:1217-1225.
6. Djomand G, Roels T, Ellerbrock T, Hanson D, et al.: Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Cote d'Ivoire. AIDS 2003;17(Suppl. 3):S5-S15.
7. Bile C, Adje-Toure C, Borget M-Y, et al.: Performance of drug resistance genotypic assays among HIV-1 infected patients with predominantly CRF02_AG strains of HIV-1 in Abidjan, Cote d'Ivoire. J Clin Virol 2005;32:60-66.
8. Lawless JF: Statistical Models and Methods for Lifetime Data. John Wiley & Sons, New York, 1982.
9. Turnbull BW: The empirical distribution function with arbitrarily grouped, censored and truncated data. J R Stat Soc Ser B 1976;38:290-295.
10. Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, et al.: Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA 2007;298:1888-1899.
11. Walker SA, Doerholt K, Sharland M, and Gibb DM, for the Collaborative HIV Paediatric Study (CHIPS) Steering Committee: Response to highly active antiretroviral therapy varies with age: The UK and Ireland Collaborative HIV Paediatric Study. AIDS 2004;18:1915-1924.
12. Pediatric European Network for treatment of AIDS (PENTA)*: Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome. AIDS 2004;18:237-245.
13. Faye A, Bertone C, Teglas JP, et al.: Early multitherapy including a protease inhibitor for human immunodeficiency virus type 1-infected infants. Pediatr Infect Dis J 2002;21:518-525.
14. Luzuriaga K, McManus M, Mofenson L, et al.: A trial of three antiretroviral regimens in HIV-1-infected children. N Engl J Med 2004;350:2471-2480.
15. Fraaij PL, Verweel G, Van Rossum AM, et al.: Sustained viral suppression and immune recovery in HIV type 1-infected children after 4 years of highly active antiretroviral therapy. Clin Infect Dis 2005;40:604-608.
16. De Rossi A: Virological and immunological response to antiretroviral therapy in HIV-1 infected children: Genotypic and phenotypic assays in monitoring virological failure. New Microbiol 2004;27:45-50.
17. Vecchi M, Burighel N, Bellanova D, et al.: Immune reconstitution in HIV-1 infected children with discordant response to antiretroviral therapies: Patterns of HIV-1 env gene evolution driven by restoration of thymic function. New Microbiol 2004;27:99-104.
18. Mullen J, Leech S, O'Shea S, et al.: Antiretroviral drug resistance among HIV-1 infected children failing treatment. J Med Virol 2002;68:299-304.
19. Linde R, Funk MB, Schuster T, et al.: Low incidence of genotypic and phenotypic resistance in paediatric HIV-infected patients on long-term first-line antiretroviral triple therapy. AIDS 2001;15:1077-1079.
20. Weidle PJ, Abrams EJ, Gvetadze R, et al.: A simplified weight-based method for pediatric drug dosing for zidovudine and didanosine in resource-limited settings. Pediatr Infect Dis J 2006;25:59-64.